Pleco Therapeutics
Nijmegen
About Pleco Therapeutics
Pleco Therapeutics' aim is to establish the market value and therapeutic potential of our patented PlecoidTM medications by focusing first on orphan cancer treatments. Current pre-clinical development activities at the firm are focused on the development of medicines for Acute Myeloid Leukaemia (AML), a relatively rare blood cancer, and Small-Cell Lung Cancer (SCLC), an aggressive subtype of lung cancer. Both diseases carry a poor prognosis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $17.2M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2022)
- Website: plecotherapeutics.com
- Phone: +31-61-132-5510
Industries & Categories
Clinical Trials, Health Care, Manufacturing, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/pleco-therapeutics-150180 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.